Vaccination and immunotherapy as new therapeutic modalities in the treatment of glaucoma
OwnerEmil William Chynninventor
Life of this patent
Estimating the term…
Abstract
This invention provides a method whereby a vaccine, particularly a vaccine based on a prophylactic or therapeutic AIDS/HIV vaccine, or other immune-reactive substance is administered to produce an immunologic response that decreases intraocular pressure or has a neuro-protective effect beneficial in the treatment of glaucoma patients. The invention may also be used as a provocative test to diagnose glaucoma as well as identify those patients at risk for developing glaucoma. The invention may also be used to prevent the development of glaucoma in patients deemed to be at high risk of developing glaucoma, such as glaucoma suspects or ocular hypertensive patients.
Claims11
A method for therapeutic treatment of glaucoma or ocular hypertension comprising administering to a human subject a composition containing an effective amount of an isolated HIV gp120 protein to decrease intraocular pressure, wherein said subject has an intraocular pressure (IOP) of 22 mm Hg or greater.
A method for reducing intraocular pressure in a human subject, comprising a) determining whether the subject has an intraocular pressure of 22 mm Hg or greater;
- and b) administering a composition containing an isolated HIV gp120 protein to a human subject that has an intraocular pressure of 22 mm Hg or greater.
Dependencies are inferred from the claim text.